UBS AM’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.5M | Buy |
509,094
+39,066
| +8% | +$1.04M | ﹤0.01% | 1209 |
|
|
2025
Q1 | $11.4M | Buy |
470,028
+6,696
| +1% | +$162K | ﹤0.01% | 1166 |
|
|
2024
Q4 | $18.6M | Sell |
463,332
-8,912
| -2% | -$359K | ﹤0.01% | 982 |
|
|
2024
Q3 | $29.9M | Sell |
472,244
-7,150
| -1% | -$453K | 0.01% | 809 |
|
|
2024
Q2 | $25.4M | Buy |
479,394
+123,806
| +35% | +$6.56M | 0.01% | 786 |
|
|
2024
Q1 | $29.2M | Sell |
355,588
-119,525
| -25% | -$9.8M | 0.01% | 700 |
|
|
2023
Q4 | $8.84M | Sell |
475,113
-3,582
| -0.7% | -$66.7K | ﹤0.01% | 1036 |
|
|
2023
Q3 | $5.3M | Buy |
+478,695
| New | +$5.3M | ﹤0.01% | 1184 |
|
|
2022
Q2 | – | Sell |
-111,159
| Closed | -$333K | – | 2777 |
|
|
2022
Q1 | $333K | Hold |
111,159
| – | – | ﹤0.01% | 2567 |
|
|
2021
Q4 | $511K | Hold |
111,159
| – | – | ﹤0.01% | 2552 |
|
|
2021
Q3 | $698K | Sell |
111,159
-18,069
| -14% | -$113K | ﹤0.01% | 2340 |
|
|
2021
Q2 | $774K | Buy |
129,228
+28,988
| +29% | +$174K | ﹤0.01% | 2345 |
|
|
2021
Q1 | $634K | Sell |
100,240
-28,400
| -22% | -$180K | ﹤0.01% | 2300 |
|
|
2020
Q4 | $724K | Buy |
128,640
+56,500
| +78% | +$318K | ﹤0.01% | 2137 |
|
|
2020
Q3 | $420K | Hold |
72,140
| – | – | ﹤0.01% | 2207 |
|
|
2020
Q2 | $520K | Sell |
72,140
-14,523
| -17% | -$105K | ﹤0.01% | 2115 |
|
|
2020
Q1 | $406K | Sell |
86,663
-861
| -1% | -$4.03K | ﹤0.01% | 2052 |
|
|
2019
Q4 | $702K | Buy |
87,524
+6,242
| +8% | +$50.1K | ﹤0.01% | 2091 |
|
|
2019
Q3 | $559K | Buy |
81,282
+15,669
| +24% | +$108K | ﹤0.01% | 2238 |
|
|
2019
Q2 | $545K | Buy |
65,613
+18,354
| +39% | +$152K | ﹤0.01% | 2174 |
|
|
2019
Q1 | $470K | Buy |
47,259
+20,459
| +76% | +$203K | ﹤0.01% | 2130 |
|
|
2018
Q4 | $205K | Buy |
+26,800
| New | +$205K | ﹤0.01% | 2387 |
|